A Study of Foscarnet Plus Ganciclovir in the Treatment of Cytomegalovirus of the Eye in Patients With AIDS Who Have Already Been Treated With Ganciclovir

Inclusion Criteria

• •Concurrent Medication:
• •Allowed:
• •Chemotherapy for Kaposi's sarcoma (excluding interferon) if patient is hematologically stable for at least 30 days prior to entry.
• •Zidovudine (AZT), dideoxyinosine (ddI), dideoxycytidine (ddC) after first two weeks of study period if absolute neutrophil count is \> 1000 cells/mm3 and hemoglobin = or \> 8 g/dl.
• •Vancomycin.
• •Fluconazole or investigational triazoles (e.g., itraconazole, SCH 39304) for disseminated fungal infection.
• •Pneumocystis carinii pneumonia prophylaxis (except parenteral pentamidine).
• •Acyclovir or other appropriate medication may be instituted in the event of the appearance of Herpes simplex virus
• •(HSV) or Varicella zoster virus (VZV) infections.
• •G-CSF or GM-CSF for grade 4 neutropenia.
• •Concurrent Treatment:
• •Allowed:
• •Recombinant human erythropoietin.
• •Prior Medication: Required:
• •Completion of 14-day course of intravenous ganciclovir induction therapy (2.5 mg/kg IV q8h or 5 mg/kg q12h for 14 days) or foscarnet induction therapy (60 mg/kg q8h adjusted for renal function for 14 days) within 1 week prior to study entry. Patients who do not initiate the study immediately upon completing ganciclovir induction therapy should receive a maintenance ganciclovir regimen of 5 mg/kg/day or 6 mg/kg/day 5 x week or a foscarnet regimen of 90-120 mg/kg/day until initiating study drug.
• •Patients must:
• •Have a diagnosis of cytomegalovirus retinitis and HIV infection.
• •Be capable of giving informed consent. Patients \< 18 years of age may participate with the consent of parent, guardian, or person with power of attorney.
• •Allowed:
• •History of seizure disorder or a central nervous system (CNS) mass lesion.